# Tesamorelin Dosage and Half-Life in the Research Literature

> Tesamorelin dosage as studied: 2 mg/day in the pivotal HIV trials, 1 mg/day in the cognition arm, the subcutaneous route, and the short plasma half-life against persistent IGF-1 elevation.

The doses administered in the trials, the subcutaneous route, and the pharmacokinetic paradox of minutes-long plasma clearance against a day-long IGF-1 effect.

## The short version

This page describes the tesamorelin dosage used in studies — it is not a how-to. In the trials, the dose was 2 mg injected under the skin once a day (1 mg in the cognition study). The peptide itself leaves the blood within minutes, but its downstream effect — raised IGF-1 (a liver-made growth signal) — lasts across the day, which is why once-daily dosing works. Research-grade tesamorelin is supplied for laboratory study; no human dosing instructions are given here, and the figures below are reported as what investigators administered, not as a recommendation.

## Tesamorelin Dosage in the Research Literature

Across the clinical record, tesamorelin dosage clusters around two figures, both administered as a once-daily subcutaneous (under-the-skin) injection. The studied dose in both pivotal Phase 3 trials — and the FDA-approved regimen — was **2 mg subcutaneously once daily** [3][4]. A lower **1 mg/day** arm was studied in the cognition trial in older adults [8] and as a lower arm in a dedicated type-2-diabetes safety trial. A later reformulation uses a higher-concentration once-daily subcutaneous regimen, but the extensively studied paradigm is the once-daily 2 mg dose.

The route is fixed. Subcutaneous injection at an abdominal site is the only route studied in clinical trials and the only FDA-approved route. These are descriptions of what was administered in studies, in defined populations, under trial supervision — not dosing guidance. Research-grade material is supplied for laboratory work and is not approved for human self-administration.

## Half-Life and Plasma Clearance

Tesamorelin's half-life is short, and that is the interesting part. Population pharmacokinetic modeling reported an apparent plasma clearance of roughly 1,060 L/h, with no clinically relevant demographic covariates and about a 13% increase in absorbed fraction by day 14 versus day 1 (Gonzalez-Sales 2015) [12]. Secondary sources — the FDA label and Mayo Clinic — describe a terminal half-life on the order of ~26-38 minutes.

The paradox is that a molecule cleared from plasma in minutes produces an effect that lasts a day. The resolution is downstream: tesamorelin's job is to trigger a pulse of endogenous growth hormone, and the resulting IGF-1 elevation persists across the once-daily dosing interval even after the peptide itself is gone [12]. The pharmacology lives in the signal it sets off, not in the molecule's own residence time — which is why once-daily dosing is sufficient despite the rapid clearance. The trans-3-hexenoic acid modification extends the molecule's activity relative to native GHRH by blocking DPP-IV cleavage [1].

## What is the half-life of tesamorelin?

Plasma exposure is short. Population PK modeling reported apparent clearance ~1,060 L/h [12]; secondary sources (FDA label, Mayo Clinic) describe a terminal half-life on the order of ~26-38 minutes. Downstream IGF-1 elevation persists across the dosing interval, supporting once-daily dosing [12].

## How long does tesamorelin stay in your system?

The peptide itself clears rapidly from plasma (clearance ~1,060 L/h), but its biological effect — IGF-1 elevation — persists over the once-daily interval [12]. The absorbed fraction rose roughly 13% by day 14 versus day 1 in population-PK analysis [12].

## Formulation and Stability

Tesamorelin is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before use; the FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window. The molecule's stability advantage over native GHRH comes from chemistry, not formulation: the trans-3-hexenoic acid group on the N-terminus blocks the DPP-IV cleavage that inactivates native GHRH within minutes [1]. Dosing in trials was once daily, consistent with both the rapid plasma clearance and the persistent downstream IGF-1 effect [12]. Research-grade powder sold for laboratory use lacks the purity and potency oversight of the approved product.

---

A lab-notebook digest of the tesamorelin record — the GHRH(1-44) chemistry sketched, the visceral-fat and IGF-1 trials and the lone cognition study jotted to their sources, and the FDA-only-for-HIV-lipodystrophy scope inked in the margin in red pen; no clinic behind the bench, nothing here compounded or for sale.